Relevance of internal time and circadian robustness for cancer patients

Elisabet Ortiz-Tudela1,2,4, Pasquale F. Innominato2,3, Maria Angeles Rol1,5*, Francis Lévi2,3,4 and Juan Antonio Madrid1

Abstract
Background: Adequate circadian timing of cancer treatment schedules (chronotherapy) can enhance tolerance and efficacy several-fold in experimental and clinical situations. However, the optimal timing varies according to sex, genetic background and lifestyle. Here, we compute the individual phase of the Circadian Timing System to decipher the internal timing of each patient and find the optimal treatment timing.

Methods: Twenty-four patients (11 male; 13 female), aged 36 to 77 years, with advanced or metastatic gastro-intestinal cancer were recruited. Inner wrist surface Temperature, arm Activity and Position (TAP) were recorded every 10 min for 12 days, divided into three 4-day spans before, during and after a course of a set chronotherapy schedule. Pertinent indexes, I < O and a new biomarker, DI (degree of temporal internal order maintenance), were computed for each patient and period.

Results: Three circadian rhythms and the TAP rhythm grew less stable and more fragmented in response to treatment. Furthermore, large inter- and intra-individual changes were found for T, A, P and TAP patterns, with phase differences of up to 12 hours among patients. A moderate perturbation of temporal internal order was observed, but the administration of fixed chronomodulated chemotherapy partially resynchronized temperature and activity rhythms by the end of the study.

Conclusions: The integrated variable TAP, together with the asynchrony among rhythms revealed by the new biomarker DI, would help in the personalization of cancer chronotherapy, taking into account individual circadian phase markers.

Keywords: Circadian, gastro-intestinal cancer, personalization, TAP, chemotherapy

Background
The circadian system controls the timing of all processes in the organism and is composed of a set of structures whose core piece lies in the suprachiasmatic nuclei of the hypothalamus (SCN) [1]. Impairment of the biological clock has been associated with an increased risk of developing several diseases, such as cancer, cognitive impairments, metabolic syndrome, cardiovascular dysfunction and immune dysregulation [2]. Moreover, circadian disruption has been reported to decrease survival of cancer patients [3–5]. This concern is so great that the International Agency for Research on Cancer has classified long-term shift work involving circadian disruption in Group 2A, meaning that it is “probably carcinogenic to humans” [6].

Knowledge of the rhythmic features of drug metabolism, cellular detoxification and cell division cycle [7] has been used to optimize cancer treatments by means of chronotherapy. Chronotherapy mainly involves chronomodulated delivery schedules, and consists of the administration of each drug according to a delivery pattern with precise circadian times in order to achieve the best tolerance and efficacy [8]. However, simpler approaches delivering a conventional treatment either during the morning or during the afternoon have also been reported [9, 10].

* Correspondence: angerol@um.es
1 Chronobiology Laboratory, Department of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain
2 Chronobiology Laboratory, Department of Physiology, Faculty of Biology, University of Murcia, Campus de Espinardo, Espinardo, Murcia Zip Code 30100, Spain
5 Chronobiology Laboratory, Department of Physiology, University of Murcia, Faculty of Biology, University of Murcia, Murcia, Spain

© 2016 Ortiz-Tudela et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Scheduled cancer chronotherapy has proven to be a reliable and advantageous alternative to fixed chemotherapy schedules, at least in men [8, 11]. However, according to previous papers from our group, chemotherapy administration produces an overall disturbance in the rest-activity rhythm, while different patterns of evolution are evident among patients [12]. Furthermore, an effect of sex on the efficacy of the treatment has also been reported [13, 14], suggesting that efficacy could be theoretically improved by personalizing treatment schedules through the use of individual circadian phase markers, as opposed to general schedules common to all patients [7, 8, 11, 12].

However, the introduction of personalized treatments should take into account circadian characteristics, which can differ not only according to the individual person, but also depending on his/her sex, age and chronotype [15–19]. The knowledge of the individual circadian system robustness could in theory, first, allow us to determine which patients might benefit from a chronomodulated therapy and second, to customize the particular timing of the chronotherapy to match up with the personal circadian time.

Nevertheless, assessing the individual circadian status and the severity of chronodisruption is still an unsolved issue, since there are not enough studies on humans attempting to decipher internal timing. Several studies have monitored the rest-activity rhythm as a biomarker of circadian functions in humans (for a review, see [20]), since this can be non-invasively recorded, even for extended periods of time using a wrist-worn accelerometer (actigraph), thus making it suitable for application in the oncology setting [20]. However, it presents certain limitations because of the existence of strong exogenous influences from the type and timing of activity schedules and artifacts, such as those related to bed partner movements or sleeping when travelling in a car or train, etc. [21, 22].

Core body temperature (CBT) is another circadian marker rhythm whose pattern is generated by the suprachiasmatic nuclei, which also acts as an effector involved in the internal coordination of peripheral clocks. However, its evaluation is not problem-free: the CBT rhythm can be determined using a rectal probe connected to an external recorder [23, 24] (a system that is neither safe nor convenient for ambulatory assessment of rhythms in cancer patients) or telemetric pills (which are very expensive and provide records that are too short). Thus, the topic of non-invasive ambulatory monitoring is attracting increasing interest, with distal skin temperature presently constituting a feasible alternative to CBT [25–27]. The peripheral skin temperature pattern is roughly opposite that of CBT: the highest temperatures occur during early night, while the lowest values are seen in the early morning, after awakening [27]; however, it is important to note that this can be masked by position or activity [28].

For this reason, the combination of different complementary circadian markers in the integrated variable TAP (Temperature, Activity, body Position) is less affected by masking factors than individual variables, and minimizes individual recording artifacts. Thus, its use has been reported to estimate the functional status of the circadian system under real life conditions [26] and to assess the sleep-wake cycle, obtaining better estimates than actigraphy alone [29]. Furthermore, TAP has been correlated to the melatonin rhythm, as a M5 calculated on TAP and the Dim Light Melatonin Onset (DLMO), considered to be the most robust phase marker, presented a correlation coefficient of 0.720 ($p = 0.006$) [30]. Moreover, the simultaneous recording of multiple overt rhythms allows us to assess their internal synchrony, constituting a first approach to evaluating whether temporal order is maintained.

The aim of the current study was to evaluate concomitantly multiparametric TAP in cancer patients undergoing fixed-scheduled chronotherapy. The primary endpoint was to evaluate the individual circadian phase and robustness at baseline. Secondary outcomes included the dynamic and continuous evaluation of chemotherapy-induced changes, the degree of internal rhythmic synchronization and the associations between baseline and on-treatment circadian parameters and clinical outcomes. This novel and unique tool provides relevant information needed to precisely optimize chronotherapy based on the patient’s individual phase, in order to improve its therapeutic index.

**Methods**

**Study design**

A descriptive, exploratory and repeated measures design was implemented in order to evaluate the dynamics of three biomarkers (Temperature, Activity and Position) of the Circadian Timing System (CTS) in cancer patients receiving a multidrug, 5-Fluorouracil-based cancer chronotherapy protocol [31]. The three circadian biomarkers were jointly recorded for 12 days, i.e. during a baseline 4-day span before chronotherapy onset, and over the next 8 days, which corresponded to treatment administration and early recovery. This recording was scheduled to take place at least 2 weeks after the previous chemotherapy onset. The present study was approved by the hospital’s internal review board and ethics committee and abided by the Helsinki Declaration of 1975 (revised in 1983). All the subjects were recruited at the Chronotherapy Unit of the Oncology Department in Paul Brousse Hospital (Villejuif, France). After full explanation of the procedure and
objectives and before being enrolled in the study, all patients gave their oral consent to participate in it.

**Eligibility criteria**
Eligibility criteria included a histological proof of solid cancer at an advanced or metastatic stage. Patients had to be at least 18 years old, with a physician-rated Performance Status (PS) of less than 3 according to the World Health Organization (W.H.O.) classification, and an estimated life expectancy of at least 6 months. Study entry required Grade < 3 in acute clinical and hematological adverse events (National Cancer Institute Common Toxicity Criteria v3.0) and a treatment-free interval of at least 2 weeks. Non-inclusion criteria were persistent grade 3-4 chronic toxicities (except alopecia), symptomatic brain metastases, concomitant severe infection, surgery during the previous month, severe heart dysfunction or ischemic disease and uncontrolled psychiatric illness.

**Chemotherapy regimens**
Non-hospitalized patients received one of four set 4-day multidrug chronotherapy protocols selected according to disease type and status [14, 32, 33]. The use of a multi-channel portable and time-programmable infusion pump (Mélodie®, Aegertant, France) enabled fixed-time chronomodulated infusions of 5-fluorouracil-leucovorin (5-FU-LV; delivered from 22:15 to 9:45, with peak rate at 4:00), oxaliplatin (I-OHP, delivered from 10:15 to 21:45, with peak rate at 16:00) and/or irinotecan (CPT-11, delivered from 2:00 to 8:00, with peak rate at 5:00) [14, 32, 33]. As indicated, cetuximab, panitumumab, bevacizumab, or docetaxel were administered over 1-2 h in the outpatient clinic, prior to chronotherapy onset.

**Toxicity assessment**
Physical examination and toxicity assessment according to NCI CTC-AE v3.0 criteria were performed both at baseline and prior to the administration of the subsequent treatment course. Blood cell counts were obtained before chronotherapy and weekly thereafter, while blood chemistry was determined at baseline and at 2 or 3 weeks. Treatment-induced grade 1 body weight loss and/or grade 2 fatigue were considered to be relevant toxicities, in view of their prior association with both circadian disruption and outcomes of chronotherapy [3, 12, 34].

**Circadian biomarkers**
The wrist temperature rhythm was continuously assessed every 10 min for 12 days using a temperature sensor (Thermochron® iButton DS1921H, Dallas, Maxim Integrated). It was attached within a double-sided cotton sport wrist band, with the sensor surface placed over the radial artery of the non-dominant hand [26–28, 30].

The body position and rest-activity rhythms were determined every 30 seconds over the same 12 days by an accelerometer inserted into a sports band. Its x-axis was set parallel to the humerus bone of the non-dominant arm (Hobo® Pendant G Acceleration Data Logger, Massachusetts, Onset Computer Corporation) [26]. Furthermore, patients were asked to complete a diary with their daily activities such as the awakening moment, main meal times, naps and going-to-bed times during the whole study.

**Biomarker data transformation**
The integrated TAP variable was computed as described in [26]. Briefly, wrist temperature (T), motor activity (A) and body position (P) data were normalized so that all values ranged between 0 and 1, after removing artifacts. High skin temperature values are usually found at night, when activity counts and position level data are lowest [26]. Therefore, wrist temperature values were inverted so that all three biomarkers appear with a similar pattern of higher counts during daytime. The mean of the normalized variables (T, A and P) was calculated for each subject. TAP values near 1 support a high activation level, as indicated by a low wrist temperature, a high level of activity and a vertical position. In contrast, near-null values correspond to a deep rest state, as indicated by a high wrist temperature, a low activity level and a horizontal position.

**Time series analyses**
The multiparametric recordings allowed the computation of the following nine parameters for each individual circadian biomarker and the integrated variable TAP at baseline, during chronotherapy, and during the early recovery period [28, 35]:

- Phase markers, including the mean value and timing of five consecutive hours with the lowest values (VL5 and L5, respectively) and the mean value and timing of ten and five consecutive hours with the highest values (VM10 and M10, and VM5 and M5, respectively). The phase markers allowed the computation of the relative amplitude (RA), which is the difference between the VM10 and VL5, divided by VM10 + VL5. To facilitate comparisons among variables, this parameter was multiplied by ten for wrist temperature.
- Interdaily Stability (IS), which provides an estimated measure of rhythm stability, ranging between 0 (Gaussian noise) to 1 (perfect rhythm stability from one day to the next).
- Intradian Variability (IV), which is an estimated measure of rhythm fragmentation, with values of 0 indicating a perfectly sinusoidal curve, and 2 Gaussian noise, respectively.
IV, IS and RA were incorporated into a single variable to yield the Circadian Function Index (CFI). CFI can be calculated as described in [26]. It oscillates between 0 (absence of circadian rhythmicity) and 1 (a robust circadian rhythm).

Each of these parameters was computed before, after and during chemotherapy. In addition, we generated full study representations (Figs. 1 and 2) of all variables analyzed, as well as mean waveforms for every period of study.

Furthermore, in order to explore the maintenance or alteration of internal temporal order [36] in cancer patients, we calculated the absolute difference between the phase markers M5 (for temperature) and L5 (for activity) for each patient and each period studied. In an ideal situation, both phase markers (midpoint of maximal temperatures and minimal activity) should be synchronized; in the worst case scenario, a 12-hour difference would be found between them. Thus, when differences reached 12 hours, the internal Desynchronization Index (DI) was considered to be 1. When no timing difference was found, DI was 0. Timing differences between 0 and 12 hours were proportionally assigned a value between 0 and 1.

**Fig. 1** Twelve-day ambulatory mean recording of TAP (a), wrist temperature (b), motor activity (c) and body position (d) (n = 24) during the study period. The mean of each variable is represented as a black line, and the SEM as a vertical grey line. Rest declared denotes the percentage of patients that declared being asleep at each time point, and is represented as a grey area on each graph for terms of comparison. The chemotherapy period is highlighted by a light grey square.
Statistical analyses
The primary endpoint was the distribution of the circadian phase and robustness parameters at baseline, and their clinical determinants. To this end, descriptive statistics were performed first. Second, differences in T, A, P and TAP parameters at baseline were assessed according to clinical features, using non-parametric tests (Kruskal-Wallis or Mann-Whitney) for ordinal variables (sex, PS, prior chemotherapy) and the Pearson correlation test for quantitative variables (age).

For secondary endpoints, descriptive statistics were obtained for each parameter in every time span. Comparisons between the distribution of the parameters according to time span and sex were made using a repeated measures ANOVA, with sex as a factor (significance level set at $p < 0.05$), followed by Bonferroni post hoc pairwise comparisons when appropriate.

Logistic regression was used to explore the predictive value of baseline CFI or DI for the occurrence of clinically relevant toxicities during the same course of chemotherapy. Associations between toxicity and chemotherapy-induced circadian disruption during or after chemotherapy administration were examined using a Kolmogorov-Smirnov $Z$ test. Given the exploratory nature of this analysis, the significance level was set at $p < 0.05$.

Wherever appropriate, data in texts and figures are expressed as mean ± SEM. Statistical analyses were performed using the PASW Statistics 18 program (SPSS, IBM, USA).

Results
Patient characteristics
Twenty-four patients were enrolled in the study, including 13 women and 11 men aged 36 to 77 years (Table 1). The majority of the patients had metastatic colorectal cancer (21 patients, 88 %), a PS of 0 (18 patients, 75 %) and had received prior chemotherapy (17 patients, 71 %). Sixteen patients (67 %) were given the 4-drug chronotherapy regimen combining irinotecan, oxaliplatin, and 5-FU-LV.
Monoclonal antibodies were combined with chronotherapy for 12 patients (50%).

Baseline circadian biomarkers
Mean waveforms for the baseline period showed coherent and reasonably strong rhythmic patterns for every variable assessed (Fig. 1, Fig. 2 and Table 2). In addition, highest wrist temperature, lowest arm activity, lowest position and highest TAP values occurred in the first half of the night, as indicated by an M5 timing (± SEM) at 03:23 ± 24 min for temperature, an L5 timing at 01:13 ± 42 min for activity, at 01:54 ± 55 min for position and at 02:33 ± 21 min for TAP in the group of 24 patients.

Individual phase markers ranged from 22:10 to 06:30 for temperature, from 22:30 to 12:10 for activity, from 21:10 to 14:00 for body position and from 22:20 to 05:20 for TAP, thus revealing a difference of up to 12 h among patients with extreme timings (Fig. 3).

Differences could be observed between women and men as early as at baseline, with women always showing stronger and less fragmented rhythms (Table 2). Thus, IS (p = 0.002), IV (p = 0.001), RA (p = 0.001), CFI (p < 0.001) and I < O (p = 0.008) for activity, and IV (p = 0.002), RA (p = 0.032), CFI (p = 0.021) and I < O (p = 0.032) for TAP were significantly different between women and men.

Circadian biomarkers during chronotherapy and post-treatment
Overall, the fixed chronotherapy protocols, together with non-time specified monoclonal antibodies for half of the patients, transiently altered the baseline 24-h patterns in all three circadian biomarkers and the integrated TAP (Fig. 1). Treatment-induced changes included a statistically significant increase in rhythm fragmentation (high IV) and lower robustness (low CFI), as compared to baseline values, for temperature, rest-activity, position and TAP (Table 2 and Fig. 2). Similar trends were found for rhythm stability (IS) and amplitude (RA), although the differences were not statistically significant. Complete recovery was evidenced by data inspection after the course of chronotherapy.

Evaluation of circadian robustness
Circadian robustness was evaluated by using the CFI from the composite variable TAP, which was previously validated in [26]. Furthermore, we studied the coherence of phase markers for wrist temperature and activity rhythms throughout the study using a new index, DI or Desynchronisation Index, which quantifies timing differences between two phase markers, M5 for wrist temperature and L5 for activity, which should be in phase in healthy subjects with proper internal temporal order.

Figure 4 shows that the administration of chemotherapy decreased the robustness of the circadian system (lower CFI values during versus before chemotherapy), as explained by the perturbation of the wrist temperature, motor activity and body position rhythms, while a similar degree of desynchronization between temperature and motor activity was maintained (similar DI values before and during chemotherapy). However, the shock of chemotherapy drugs administered in a chronomodulated fashion seemed to produce the re-synchronization of at least temperature and activity rhythms, and a reinforcement of circadian robustness, which was achieved after the administration of chemotherapy (Fig. 4). An example of this disruption of the temporal internal order can be found in Fig. 5, which shows temperature and activity rhythms for two patients.

Table 1 Characteristics of patients enrolled in the study

| Age | 63 y.o. (range: 37 – 78) |
|-----|--------------------------|
| Sex | Male 11, Female 13 |
| Primary Tumor | Colon or rectal 21, Pancreas 2, Esophagus/cardia 1 |
| Number of metastatic sites | 0, 1, 2, ≥3 |
| WHO-PS | 0, 1, 2, 3 |
| Number of prior CT lines | 0, 1, 2, ≥3 |
| CT regimen | Chrono FLO 1, Chrono IF 1, Chrono IFL 1, Chrono IFLO 9 |

All information was collected before the patients’ inclusion in the study and refers to their previous medical history. Age is expressed as median and range. CT regimen is highlighted in bold. Additional chemotherapy drugs added to the protocol have been marked with (+), whenever necessary. WHO-PS: Performance Status according to the classification of the World Health Organization. CT regimen followed for chemotherapy treatment. For details, please see the material and methods section.
Table 2. IS, IV, RA, I < O and CFI calculated for wrist temperature, motor activity, body position and the composite variable TAP rhythms for the whole group (n = 24), and for each sex.

|                  | Temperature (mean ± SEM) | Motor activity (mean ± SEM) | Body position (mean ± SEM) | TAP (mean ± SEM) |
|------------------|--------------------------|----------------------------|---------------------------|-----------------|
|                  | Before | During | After | Before | During | After | Before | During | After | Before | During | After | Before | During | After |
| WHOLE GROUP      |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |
| (n = 24)         |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |
| IS 0.46 ± 0.03   | 0.39 ± 0.02 | 0.41 ± 0.02 | 0.48 ± 0.04 | 1.01 ± 0.03 | 1.01 ± 0.03 | 1.35 ± 0.03 | 1.43 ± 0.03 | 1.37 ± 0.03 |
| IV 0.18 ± 0.02 ab| 0.21 ± 0.02 | 1.10 ± 0.05 | 0.41 ± 0.03 | 0.40 ± 0.03 | 0.42 ± 0.03 | 0.54 ± 0.03 | 0.64 ± 0.03 | 0.65 ± 0.02 |
| RA 0.33 ± 0.03 b | 0.47 ± 0.03 | 0.51 ± 0.03 | 0.57 ± 0.03 | 0.55 ± 0.03 | 0.66 ± 0.02 | 0.65 ± 0.03 | 0.70 ± 0.03 | 0.65 ± 0.02 |
| CFI 0.61 ± 0.02 ab| 0.62 ± 0.02 | 83.88 ± 3.22 | 83.26 ± 2.93 | 78.26 ± 2.89 | 90.71 ± 2.19 |
| I < O            |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |
| WOMEN            |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |
| (n = 13)         |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |
| IS 0.56 ± 0.03   | 0.32 ± 0.02 | 0.36 ± 0.02 | 0.40 ± 0.04 | 1.11 ± 0.04 | 1.78 ± 0.08 | 1.09 ± 0.08 | 1.45 ± 0.04 | 0.49 ± 0.06 | 0.55 ± 0.05 | 0.45 ± 0.04 | 0.52 ± 0.04 | 0.58 ± 0.06 |
| IV 0.15 ± 0.02 ab| 0.22 ± 0.02 | 0.30 ± 0.03 | 0.53 ± 0.06 | 0.41 ± 0.06 | 0.44 ± 0.05 | 0.54 ± 0.05 | 0.59 ± 0.04 | 0.57 ± 0.05 | 0.61 ± 0.05 |
| RA 0.34 ± 0.04  | 0.58 ± 0.04 | 0.61 ± 0.03 | 75.04 ± 5.95 | 75.00 ± 5.76 | 76.26 ± 3.99 | 84.51 ± 6.19 | 85.61 ± 5.65 | 85.98 ± 3.77 |
| CFI 0.59 ± 0.06  | 0.64 ± 0.04 | 0.44 ± 0.02 | 0.42 ± 0.03 | 0.53 ± 0.04 | 0.50 ± 0.03 | 0.48 ± 0.05 | 0.68 ± 0.04 | 0.61 ± 0.03 | 0.65 ± 0.04 |
| I < O            |        |        |       |        |        |       |        |        |       |        |        |       |        |        |       |

Repeated-measures ANOVA and post hoc Bonferroni were performed to verify the differences among periods for the whole group or for each sex. Statistical significance was set at $p < 0.05$.

Different letters indicate statistically significant differences between periods (also highlighted in bold). Different numbers indicate significant differences between men and women for each variable and studied period.
Sex-dependent response of circadian biomarkers to the fixed chronotherapy protocol

The fixed chronotherapy protocols resulted in a significantly greater deterioration of TAP rhythms in women than in men, despite the fact that baseline rhythms were found to be more robust in women (Table 2). However, this sex-dependent effect was not consistent for every studied variable, probably due to the small sample size.

Toxicity

A single patient displayed grade 4 neutropenia. No other hematological or clinical grade 3 or 4 toxicity was encountered. The most frequent adverse events consisted of grade 1 or 2 diarrhea (67 % of the patients), fatigue (58 %), anorexia (46 %), mucositis (46 %) and peripheral sensory neuropathy (46 %).

A body weight loss >5 % and a fatigue ≥ grade 2 were experienced by 5 and 9 patients, respectively, following chronotherapy. Baseline CFI and DI did not predict the occurrence of any toxicity. Interestingly, those patients with this clinically relevant weight loss or fatigue displayed a higher DI during chronotherapy (median = 0.22), as compared to the patients without such toxic symptoms (median = 0.10; \( p = 0.04 \)).

Discussion

This study has shown for the first time that in cancer patients the circadian system presents a huge variability in terms of phase distribution (12 hour spread among different patients) (Fig. 3) and more importantly, a moderately perturbed temporal internal order (Fig. 4). This was evaluated through the concomitant and continuous measurement of 3 different circadian biomarkers (T, A, P). This monitoring is feasible in cancer patients receiving chemotherapy on an outpatient basis, using non-invasive devices that are readily tolerated by patients for 12 days, without significant complaints. Moreover, we observed that the chronomodulated administration of chemotherapy affected the robustness of the circadian
system, increasing fragmentation and diminishing the stability of wrist temperature, motor activity and body position rhythms during the treatment (Table 2). Surprisingly, the chronochemotherapy was able to partially resynchronize the rhythms studied, leading to reduced perturbation of the internal temporal order after the treatment.

In cancer patients, the rest-activity rhythm has been reported to be altered even before the administration of chemotherapy [4, 5, 37, 38]. Previous studies have shown that chemotherapy induces rapid-onset and sustained alterations in the rest-activity rhythm in most cancer patients [12, 37, 39, 40]. The present study confirms this finding and extends these results to wrist temperature, body position and TAP rhythms, which were also perturbed to a large extent by chemotherapy.

The consequences of a disturbed circadian system in cancer patients have been previously described with respect to rest-activity and cortisol rhythms. In this sense, having a robust rest-activity rhythm increases overall survival [3–5]. Furthermore, a flattened cortisol rhythm or disturbed sleep pattern in cancer patients is linked to a higher risk of early death and shorter overall survival [41–47]. Given the importance of these facts, future

![Fig. 5 Wrist temperature and activity pattern for two patients, one with a low DI between wrist temperature and motor activity rhythms (a) and other with a high DI (b). Mean waveforms for the baseline pre-chemo period (4 days) are represented. Wrist temperature rhythm is drawn as a solid black line and motor activity is shown as grey bars. In addition, the five consecutive hours of maximal and minimal values for temperature and motor activity and their central timing (M5 and L5, respectively) are indicated by grey rectangles. Wrist temperature error (the standard error of the mean, SEM) is represented by dotted lines above and below the wrist temperature series. Motor activity SEM is omitted in this figure for reasons of clarity. a corresponds to a patient with a DI = 0.00; note that M5 = 03:50 h and L5 = 03:50 h coincide. b corresponds to a patient with a DI = 0.63; note not only the difference in timing for M5 = 04:40 h; L5 = 12:10 h, but also the lack of any overlapping]
studies should specifically evaluate the effect of diminishing disruption, including sleep disruption, on survival in cancer.

A challenged internal temporal order, as observed after long-haul transmeridian flights or rotating or night shift work, increases the risk of developing certain types of cancer, diabetes or metabolic syndrome and cardiovascular diseases [48, 49]. However, no data to date are available on the internal temporal order of cancer patients. Here, to the best of our knowledge, we provide the first evaluation of the internal synchronization of patients already suffering from advanced cancer. In this study, we were able to quantify the internal rhythmic coherence of our patients throughout a course of chemotherapy. We found that, in the presence of moderate desynchronization at baseline, chronomodulated chemotherapy was, on average, able to partially re-synchronize these rhythms by the end of the study. This demonstrates the usefulness of circadian-based chemotherapy, at least in reducing desynchrony among the internal rhythms in these patients. However, the limited number of patients enrolled in this study prevent for definitive conclusions on the clinical outcomes of prolonged internal desynchronization. Thus, more extensive future studies should address the implications of this finding on the survival rates of these patients.

Sex differences in the effect of chronomodulated treatments for colorectal cancer have previously been described [13, 14]. Our results showed some rhythmic differences according to sex but not enough to draw any definitive conclusions. Comprehensive studies with a larger sample of patients would be needed to that effect.

The large inter-individual differences, up to 12 hours, among patients already observed at baseline were also found consistently throughout the study, both during and immediately after the administration of chemotherapy. This variability could potentially affect the safety and efficacy of cancer treatments. The administration of chemotherapy schedules in a chronomodulated fashion attempts to find the optimal timing of maximum antitumor activity and minimum side effects for the host [11], which has been proven effective in both murine models (mostly male mice) [11, 50] and humans [3, 7, 51]. Up to now, these schedules have been administered without considering the individual phase of each patient’s rhythms, and thus the hypothesis of administration at the optimal moment is challenged. Therefore, this study establishes the proof of principle for future studies focused on the individualization of cancer treatment, based not only on population studies, but also on individual circadian rhythm phases.

Evidence exists in the literature regarding the benefits of chronoenhancement in cancer patients, either through the administration of melatonin [52], or by optimally-timed exposure to bright light [53]. Therefore, other circadian therapeutic approaches, including sleep hygiene and regular feeding schedules, could be implemented in order to restore circadian function or to prevent chemotherapy-induced circadian disruption. In mice, for example, circadian amplification of the core body temperature rhythm through meal timing has been observed to cut experimental cancer growth in half [54]. These chronoenhancement techniques could potentially be useful to strengthen and synchronize cancer patients’ circadian system prior to chemotherapy administration, especially for those patients with persistent circadian disruption. This methodology would hypothetically, on the one hand, find the optimal time for their treatment and on the other hand, maximize treatment efficacy once administered at the right individual time.

**Conclusions**

In summary, both experimental and clinical data support the relevance of a robust circadian system in order to enhance the efficacy and tolerability of chronomodulated treatments. Thus, reliable, non-invasive and continuously assessed circadian biomarkers, such as those provided by the rest-activity, body position and temperature monitoring computed in the integrated variable TAP are required to optimize cancer treatments, taking into account the status and phase of individual circadian systems. The great inter-patient variability at baseline, during and after treatment, and the differing profound effects of chemotherapy on circadian robustness, phase and internal order synchronization confirm the interest of such multiparametric evaluation of cancer outpatients. The useful information provided by this concomitant TAP monitoring is also relevant for interventional studies targeting the circadian timing system, in order to enhance or protect its function, with the aim of improving the wellbeing and outcomes of cancer patients.

**Abbreviations**

**TAP:** integrated variable composed of wrist Temperature, motor Activity and body Position; I < O: dichotomy index In bed < Out of bed; DI: Desynchronization Index; SCN: SupraChiasmatic Nuclei of the hypothalamus; CBT: Core Body Temperature; DLMO: Dim Light Melatonin Onset; CTS: Circadian Timing System; PS: Performance Status; W.H.O.: World Health Organization; 5-FU-LV: 5-Fluorouracil; CPT-11: Irinotecan; NCI CTC-AE v3.0: National Cancer Institute’s Common Terminology Criteria for Advance Events version 3.0; VL5: mean value of five consecutive hours with the lowest values; L5: mean timing of five consecutive hours with the highest values; VM5: mean value of five consecutive hours with the highest values; VM10: mean value of ten consecutive hours with the highest values; M10: mean timing of ten consecutive hours with the highest values; RA: Relative Amplitude; IS: Interdaily Stability; IV: Intradaily Variability; CFI: Circadian Functioning Index; ANOVA: ANalysis Of VAriance; SEM: Standard Error of the Mean; CT: chemotherapy; y.o.: years old.

**Competing interests**

All authors declare that they have no conflicts of interest, as no private funding was obtained for the performance of this study.
**Authors’ contributions**

EOT participated in the conception and design, development of methodology, data acquisition, analysis and interpretation; and writing and revision of the manuscript. PI participated equally in the conception and design, data acquisition, study supervision; and writing and revision of the manuscript. MAR was involved in the conception and design, development of methodology, analysis and interpretation of data and revision of the manuscript. FL participated in the conception and design, data acquisition, study supervision, and writing and revision of the manuscript. MAR was involved in the conception and design, development of methodology, analysis and interpretation of data and revision of the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

Financial support has been provided by the Instituto de Salud Carlos III, the Ministry of Science and Innovation and the Ministry of Economy and Competitiveness through the Ageing and Frailty Cooperative Research Network, RETICEF (RD12/0043/0011), SAF2013-49132-C2-1-R, including FEDER cofunding granted to J. A. Madrid, as well as by the Seneca Foundation (19410/PV/14).

*Association pour la Recherche sur le Temps Biologique et la Chronothérapie* (ARTBC International, Paul Brousse Hospital, Villejuif, France), and the European Union through the ICT-PSP project “Integrated Network for Completely Assisted Senior Citizen’s Autonomy” (IN CASA, grant agreement No. 250505) granted to Francis Lévi. We wish to thank M. Martinez for kindly reviewing the manuscript. We sincerely thank the patients and the nursing staff at the Chronotherapy Unit of the Oncology Department at Paul Brousse hospital for their contribution to this study.

**Author details**

1. Chronobiology Laboratory, Department of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
2. INSERM, UMRS 776 « Biological Rhythms and Cancers », Villejuif, France.
3. APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse Hospital, Villejuif, France.
4. Warwick Medical School, Cancer Chronotherapy Unit, Coventry, UK.
5. Chronobiology Laboratory, Department of Physiology, Faculty of Biology, University of Murcia, Campus de Espinardo, Espinardo, Murcia Zip Code 30100, Spain.

**Received**: 13 July 2015 **Accepted**: 15 April 2016 **Published online**: 21 April 2016

**References**

1. Swaab DF, Fliers E, Partman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985;342:237–44.
2. Evans JA, Davidson AJ. Health consequences of circadian disruption in humans and animal models. Prog Mol Biol Transl Sci. 2013;119:283–323.
3. Innocinatou PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Moreau T, Rol MA, Madrid JA, Mormont MC, Waterhouse J, Lévi FA. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012;131:2684–92.
4. Innocinatou PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Moreau T, Garufi C, Waterhouse J, Mormont MC, Waterhouse J, Lévi FA, Bjarnason GA, Chronotherapy Group of the European Organization for Research and Treatment of Cancer. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer. 2009;116:5557–60.
5. Mormont MC, Waterhouse J, Bhezen P, Giacchetti S, Jamil A, Bogdan A, Lellouch J, Misset JL, Toutou Y, Lévi F. Marked 24-h rest-activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038–45.
6. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Alavanja MC, Benbrahim-Tallaa L, Lissowski D, Coglanova V. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065–72.
7. Ortiz-Tudela E, Metyrek A, Ballesta A, Innocinatou PF, Lévi F. (2013). Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol. (217): 261–88.
8. Lévi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv. 2011;8:1535–41.
9. Rahn 3rd DA, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O’Quigley JM, Rich T. Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer. 2011;117:14–20.
10. Schmiegelow K, Glomstein A, Kristinsson J, Salmi T, Schröder B, Björk O. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol. 1997;19:102–9.
11. Lévi F, Okyar A, Dulong S, Innocinatou PF, Clarambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377–421.
12. Ortiz-Tudela E, Lurisch I, Beau J, Karaboue A, Moreau T, Rol MA, Madrid JA, Lévi F, Innocinatou PF. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2014A;134: 2171–25.
13. Giacchetti S, Dugué PA, Innocinatou PF, Bjarnason GA, Focan C, Garufi C, Turqillo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F, Bjarnason GA. International Chronotherapy Group. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 2012;23:3110–6.
14. Giacchetti S, Bjarnason GA, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humbert Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schneider J, Anciencia N, Lentiz MA, Baron B, Gorilla T, Lévi F. European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2006;24:3562–9.
15. Adan A, Natale V. Gender differences in morningness-eveningness preference. Chronobiol Int. 2002;19:709–20.
16. Duffy JF, Cain SW, Chang AM, Phillips AJK, Grönlund C, Wyatt JK, Dijk DJ, Wright KP Jr, Cesler IA. Quantification of Behavior Sacker Colloquium: Sex difference in the near-24-hour intrinsic period of the human circadian timing system. Proc Natl Acad Sci U S A. 2011;108 Suppl 15:15602–8.
17. Roenneberg T, Kantermann T, Jud M, Vetter C, Allebrandt KV. (2013). Light exposure and the human circadian clock. Handb Exp Pharmacol. (217): 311–31.
18. Roenneberg T, Kuehnle T, Jud M, Kantermann T, Allebrandt K, Gjördirn M, Moren M. Epidemiology of the human circadian clock. Sleep Med Rev. 2007; 11:429–49.
19. Vink JM, Groot AŠ, Kerkhof GA. Sleep disorders. Sleep Med Rev. 2004;8:139–60.
20. Aricò-Israeli S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003; 26:342–92.
21. ACBC LeBourgeois MK. Actigraphy. Respir Care Clin N Am. 2006;12:233–8. vii.
22. Sadeh A, Acebo C. The role of actigraphy in sleep medicine. Sleep Med Rev. 2002;6:113–24.
23. Klauck K. How is the circadian rhythm of core body temperature regulated? Clin Auton Res. 2002;12:147–9.
24. Waterhouse J, Drust B, Weiner D, Edwards B, Gregson W, Atkinson G, Sorensen TL, Kao S, Azawwa S, Reilly T. The circadian rhythm of core body temperature: origin and some implications for exercise performance. Chronobiol Int. 2005;22:207–25.
25. Martínez-Nicolás A, Ortiz-Tudela E, Madrid JA, Rol MA. Crossover between External Light and Internal Time in Humans. Chronobiol Int. 2011; 28:167–197.
26. Ortiz-Tudela E, Martínez-Nicolás A, Campos M, Rol MA, Madrid JA. A new integrated variable based on thermometry, actmetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol. 2010;6 e1000996.
27. Sarabia JA, Rol MA, Mendiola P, Madrid JA. Circadian rhythm of wrist temperature in normal-living subjects A candidate of new index of the circadian system. Physiol Behav. 2008;95:570–80.
28. Martínez-Nicolás A, Ortiz-Tudela E, Rol MA, Madrid JA. Uncoupling different masking factors on wrist skin temperature rhythm in free-living subjects. PLoS One. 2013;8 e61142.
29. Ortiz-Tudela E, Martínez-Nicolás A, Albares J, Segarra F, Campos M, Estivill E, Rol MA, Madrid JA. Ambulatory ChronoMonitorating (ACM) based on...
Thermometry, motor Activity and body Position (TAP): A comparison with polysomnography. Physiol Behav. 2014B;126:30–8.
30. Bonmati-Carton MA, Middleton B, Revell V, Skene DJ, Rol MA, Madrid JA. Circadian phase assessment by ambulatory monitoring in humans: Correlation with dim light melatonin onset. Chronobiol Int. 2013;31:37–51.
31. Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Hennard D, Baron B, Kreuz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007;59:10:1015–35.
32. Garufi C, Vanni B, Aschelter AM, Zappalà AR, Bria E, Nistico C, Sperduti I, Cognetti F, Terzoli E. Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur J Cancer. 2006;42:6208–16.
33. Ghodam D, Giacchetti S, Brézault-Bonnet C, Bouchanda M, Hauteville D, Adam R, Ducot B, Ghémard O, Kustlinger F, Jasmin C, Lévi F. Chronomodulated irinotecan, oxaliplatin, and 5-fluorouracil/oxaliplatin as an adjuvant salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 2006;11:1072–80.
34. Innominato PF, Giacchetti S, Moreau T, Bjarmason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Turnolo S, Carvalho C, Karaboué A, Ponct A, Speigel D, Lévi F. International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group. Fatigue and weight loss predect survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013;119:2564–73.
35. Van Someren EW, Swaab DF, Colenda CC, Cohen W, McCall WW, Rosenquist PB. Bright Light Therapy: Improved Sensitivity to its Effects on Rest-activity Rhythms in Alzheimer Patients by Application of Nonparametric Methods. Chronobiol Int. 1999;16:505–18.
36. Enren TC, Reiter RJ. Defining chronodisruption. J Pineal Res. 2009;46:245–7.
37. Ancoli-Israel S, Liu L, Marler MR, Parker BA, Sadler GR, Dimsdale J, Cohen-Zion M, Fiorentino L. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006;14:201–9.
38. Berger AM, Farr LA, Kuhn BR, Fischer F, Agramawal S. Values of Sleep/Wake, Activity/Rest, Circadian Rhythms, and Fatigue Prior to Adjuvant Breast Cancer Chemotherapy. J Pain Symptom Manag. 2007;33:398–409.
39. Berger AM, Wiegus K, Hertzog M, Fischer F, Farr L. Patterns of circadian activity rhythms and their relationships with fatigue and depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer. 2010;18:105–14.
40. Savard J, Liu L, Natarajan L, Risling MB, Neukrug AB, He F, Dimsdale JE, Mills PJ, Parker BA, Sadler GR, Ancoli-Israel S. Breast Cancer Patients have Progressively Impaired Sleep-Wake Activity Rhythms during Chemotherapy. Sleep. 2009;32:1155–60.
41. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. The circadian timing system in clinical oncology. Ann Med. 2014;46:191–207.
42. Lévi F, Duguel PA, Innominato P, Karaboué A, Dispersyn G, Parganlija A, Giacchetti S, Moreau T, Focan C, Waterhouse J, Spiegel D. ARTBC Chronotherapy Group. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 2014;31:891–900.
43. Palesh O, Aldridge-Gerry A, Ulusakarya A, Ortiz-Tudela E, Capuron L, Innominato PF. Sleep disruption in breast cancer patients and survivors. J Natl Compr Canc Netw. 2013;11:1523–30.
44. Ortiz-Tudela E. (2014C). Crossstalk between sleep disturbances and cancer survival. Sleep Med. pii: S1389-9457(14)00484-5
45. Septon SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhambhar FS, Spiegel D, Salmon P. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 2013;30(Suppl):S163–70.
46. Septon SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000.
47. Schreif A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 2015;53:256–67.
48. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.
49. Schernhammer ES, Feskanich D, Liang G, Han J. Rotating night-shift work and lung cancer risk among female nurses in the United States. Am J Epidemiol. 2013;178:1434–41.
50. Li XM, Lévi F. Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J Biol Rhythms. 2007;22:159–66.